SQZ Biotechnologies (SQZB) Stock Price, News & Analysis

Company Overview

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.01 to $0.12
• Volume: 6,904 shs
• Average Volume: 85,173 shs
• Market Capitalization: $737,275.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQZ Biotechnologies Stock Analysis - MarketRank™

SQZ Biotechnologies scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SQZ Biotechnologies.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of SQZ Biotechnologies is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SQZ Biotechnologies is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SQZ Biotechnologies has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the outstanding shares of SQZ Biotechnologies have been sold short.

Short Interest Ratio / Days to Cover

SQZ Biotechnologies has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SQZ Biotechnologies does not currently pay a dividend.

Dividend Growth

SQZ Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the outstanding shares of SQZ Biotechnologies have been sold short.

Short Interest Ratio / Days to Cover

SQZ Biotechnologies has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for SQZ Biotechnologies this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SQZ Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.00% of the stock of SQZ Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.41% of the stock of SQZ Biotechnologies is held by institutions.

SQZB Stock Analysis - Frequently Asked Questions

How have SQZB shares performed this year?

SQZ Biotechnologies' stock was trading at $0.0199 at the start of the year. Since then, SQZB shares have increased by 25.6% and is now trading at $0.0250.
View the best growth stocks for 2024 here.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SQZ Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SQZB
• CUSIP: N/A
• CIK: 1604477
• Web: www.sqzbiotech.com
• Phone: 617-758-8672
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $21.48 million
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 29,491,000
• Free Float: 24,772,000
• Market Cap: $737,275.00
• Optionable: N/A
• Beta: 1.51